Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T82028
|
||||
Former ID |
TTDR00347
|
||||
Target Name |
Sodium/hydrogen exchanger 1
|
||||
Gene Name |
SLC9A1
|
||||
Synonyms |
APNH; Myocardial Na+/H+ exchanger; NHE-1; Na(+)/H(+) exchanger 1; Na(+)Sodium/hydrogen exchanger 1/H(+) exchanger 1; Na+/H+ antiporter, amiloride-sensitive; SLC9A1
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Angina pectoris [ICD9: 413; ICD10: I20] | ||||
Cardiac arrhythmias [ICD9: 427; ICD10: I47-I49] | |||||
Heart arrhythmia [ICD10: I47-I49] | |||||
Myocardial infarction [ICD9: 410; ICD10: I21, I22] | |||||
Function |
Involved in pH regulation to eliminate acids generated by active metabolism or to counter adverse environmental conditions. Major proton extruding system driven by the inward sodium ion chemical gradient. Plays an important role in signal transduction.
|
||||
BioChemical Class |
Monovalent cation:proton antiporter
|
||||
Target Validation |
T82028
|
||||
UniProt ID | |||||
Sequence |
MVLRSGICGLSPHRIFPSLLVVVALVGLLPVLRSHGLQLSPTASTIRSSEPPRERSIGDV
TTAPPEVTPESRPVNHSVTDHGMKPRKAFPVLGIDYTHVRTPFEISLWILLACLMKIGFH VIPTISSIVPESCLLIVVGLLVGGLIKGVGETPPFLQSDVFFLFLLPPIILDAGYFLPLR QFTENLGTILIFAVVGTLWNAFFLGGLMYAVCLVGGEQINNIGLLDNLLFGSIISAVDPV AVLAVFEEIHINELLHILVFGESLLNDAVTVVLYHLFEEFANYEHVGIVDIFLGFLSFFV VALGGVLVGVVYGVIAAFTSRFTSHIRVIEPLFVFLYSYMAYLSAELFHLSGIMALIASG VVMRPYVEANISHKSHTTIKYFLKMWSSVSETLIFIFLGVSTVAGSHHWNWTFVISTLLF CLIARVLGVLGLTWFINKFRIVKLTPKDQFIIAYGGLRGAIAFSLGYLLDKKHFPMCDLF LTAIITVIFFTVFVQGMTIRPLVDLLAVKKKQETKRSINEEIHTQFLDHLLTGIEDICGH YGHHHWKDKLNRFNKKYVKKCLIAGERSKEPQLIAFYHKMEMKQAIELVESGGMGKIPSA VSTVSMQNIHPKSLPSERILPALSKDKEEEIRKILRNNLQKTRQRLRSYNRHTLVADPYE EAWNQMLLRRQKARQLEQKINNYLTVPAHKLDSPTMSRARIGSDPLAYEPKEDLPVITID PASPQSPESVDLVNEELKGKVLGLSRDPAKVAEEDEDDDGGIMMRSKETSSPGTDDVFTP APSDSPSSQRIQRCLSDPGPHPEPGEGEPFFPKGQ |
||||
Drugs and Mode of Action | |||||
Inhibitor | 5'-(N-ethyl-N-isopropyl)amiloride | Drug Info | [528830] | ||
BIIB-513 | Drug Info | [543981] | |||
CARIPORIDE | Drug Info | [530180] | |||
ENIPORIDE | Drug Info | [534705] | |||
HOE-694 | Drug Info | [534413] | |||
Homoserine Lactone | Drug Info | [551393] | |||
N-(3-Methanesulfonyl-4-methoxy-benzoyl)-guanidine | Drug Info | [534413] | |||
N-(3-Methanesulfonyl-4-methyl-benzoyl)-guanidine | Drug Info | [534413] | |||
N-(4-Bromo-3-methanesulfonyl-benzoyl)-guanidine | Drug Info | [534413] | |||
N-(4-Chloro-3-methanesulfonyl-benzoyl)-guanidine | Drug Info | [534413] | |||
N-(4-Cyano-3-methanesulfonyl-benzoyl)-guanidine | Drug Info | [534413] | |||
N-(5-m-Tolyl-furan-2-carbonyl)-guanidine | Drug Info | [527509] | |||
N-(5-Methanesulfonyl-2-methyl-benzoyl)-guanidine | Drug Info | [534413] | |||
N-(5-o-Tolyl-furan-2-carbonyl)-guanidine | Drug Info | [527509] | |||
N-(5-Phenyl-furan-2-carbonyl)-guanidine | Drug Info | [527509] | |||
N-[2-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine | Drug Info | [528720] | |||
N-[4-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine | Drug Info | [528720] | |||
N-[5-(2-Ethyl-phenyl)-furan-2-carbonyl]-guanidine | Drug Info | [527509] | |||
N-[5-(2-Nitro-phenyl)-furan-2-carbonyl]-guanidine | Drug Info | [527509] | |||
Zoniporide hydrochloride | Drug Info | [526547], [531635] | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
DRM | DRM Info | ||||
Pathways | |||||
KEGG Pathway | cAMP signaling pathway | ||||
Cardiac muscle contraction | |||||
Adrenergic signaling in cardiomyocytes | |||||
Regulation of actin cytoskeleton | |||||
Thyroid hormone signaling pathway | |||||
Salivary secretion | |||||
Gastric acid secretion | |||||
Pancreatic secretion | |||||
Bile secretion | |||||
Proteoglycans in cancer | |||||
Pathway Interaction Database | Endothelins | ||||
RhoA signaling pathway | |||||
ErbB1 downstream signaling | |||||
Signaling mediated by p38-alpha and p38-beta | |||||
Reactome | Hyaluronan uptake and degradation | ||||
WikiPathways | Regulation of Actin Cytoskeleton | ||||
G Protein Signaling Pathways | |||||
Glycosaminoglycan metabolism | |||||
Osteoclast Signaling | |||||
References | |||||
Ref 526547 | Zoniporde: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1). Cardiovasc Drug Rev. 2003 Spring;21(1):17-32. | ||||
Ref 534245 | Effect of Hoe 694, a novel Na(+)-H+ exchange inhibitor, on intracellular pH regulation in the guinea-pig ventricular myocyte. Br J Pharmacol. 1996 Aug;118(8):1905-12. | ||||
Ref 526547 | Zoniporde: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1). Cardiovasc Drug Rev. 2003 Spring;21(1):17-32. | ||||
Ref 527509 | J Med Chem. 2005 Apr 21;48(8):2882-91.(5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1. | ||||
Ref 528720 | Bioorg Med Chem Lett. 2007 May 1;17(9):2430-3. Epub 2007 Feb 17.Benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines as novel Na+/H+ exchanger inhibitors, synthesis and protection against ischemic-reperfusion injury. | ||||
Ref 528830 | J Biol Chem. 2007 Jul 6;282(27):19716-27. Epub 2007 May 10.NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity. | ||||
Ref 530180 | Eur J Med Chem. 2009 Sep;44(9):3771-6. Epub 2009 May 5.Synthesis and bioactivity of substituted indan-1-ylideneaminoguanidine derivatives. | ||||
Ref 531635 | Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. | ||||
Ref 534413 | J Med Chem. 1997 Jun 20;40(13):2017-34.(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. | ||||
Ref 534705 | J Med Chem. 1998 Sep 10;41(19):3736-47.Bicyclic acylguanidine Na+/H+ antiporter inhibitors. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.